Background: Elevated levels of Hepatocyte Growth Factor (HGF) have been observed in patients with systemic amyloidosis but little is known about HGF and other biomarkers in patients with cardiac amyloid. We hypothesized that HGF levels can discriminate patients with cardiac amyloid from those with left ventricular hypertrophy (LVH) and diastolic heart failure (DHF) who are morphologically indistinct on echocardiography (echo).
1.5 ± 0.4 1.6 ± 0.6 1.7 ± 0.4 NS End-diastolic dimension, cm 4.3 ± 0.4 4.5 ± 0.9 4.7 ± 0.9 NS End-systolic dimension, cm 3.1 ± 0.5 3.0 ± 1.0 3.1 ± 1.1 NS Left atrial dimension, cm 4.3 ± 0.6 4.5 ± 0.7 4.6 ± 1.0 NS HGF, pg/mL 2097 ± 5424 165.1 ± 58.4 162.4 ± 65.0 < 0.001 for amyloid vs. LVH < 0.001 for amyloid vs. DHF = 0.7 for LVH vs. DHF Conclusions: HGF is markedly elevated in patients with cardiac amyloidosis and may help diagnose cardiac amyloidosis in patients with LVH and DHF who are echocardiographically indistinct. These findings suggest that measurement of HGF can be confirmatory for the diagnosis of cardiac amyloid and may minimize the need for invasive or extensive testing.
